Sparavigna Adele, La Gatta Annalisa, Bellia Gilberto, La Penna Laura, Giori Andrea Maria, Vecchi Gabriele, Tenconi Beatrice, Schiraldi Chiara
DERMING Srl., Milan, Italy.
Department of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology, School of Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Clin Cosmet Investig Dermatol. 2020 Sep 16;13:683-690. doi: 10.2147/CCID.S262839. eCollection 2020.
The primary aim of this study was to evaluate the performance of the study product, in terms of volumizing activity as well as the duration of the effect, in women with age-related midfacial volume defects. In addition, the study allowed the evaluation of the tolerability of the product by both volunteers and investigators.
Twenty-two female volunteers, aged 42-60 years, participated in this study, which was performed under dermatological control in a single center. After an initial visit at baseline to verify adherence to the protocol criteria, volunteers received an injection of Aliaxin SV (IBSA Farmaceutici Italia Srl), followed 3-4 weeks later by a second touch-up treatment to treat eventual asymmetries. Four subsequent visits, the last performed 9 months from the first injection, were performed to evaluate clinically and instrumentally the efficacy of the treatment.
Clinical and statistically significant improvement in cheek volume was recorded after the first postinjection visit, and the effect was maintained until the end of the study period. A clinically measurable amelioration of wrinkle severity was also observed. By 3D picture recording and subsequent quantitative analysis, it was possible to determine the efficacy in terms of increased facial volume, which was already appreciable at the first visit, was further increased at the second and third visits and was maintained at the fourth and last visits. The injections were very well tolerated by the volunteers, as determined by their self-evaluation questionnaires.
The results of the study confirm the esthetic performance of the study product on age-related midfacial volume defects. The very strong high-volumizing activity of the study product was not only properly determined by the investigators but also confirmed by self-evaluation by the volunteers. These effects were obtained with no appreciable undesired effects.
本研究的主要目的是评估研究产品对患有与年龄相关的面部中部容积缺陷的女性在增加容积活性以及效果持续时间方面的表现。此外,该研究还允许评估志愿者和研究者对该产品的耐受性。
22名年龄在42至60岁之间的女性志愿者参与了本研究,该研究在单一中心的皮肤科控制下进行。在基线期进行首次访视以核实是否符合方案标准后,志愿者接受了Aliaxin SV(意大利IBSA制药公司)的注射,3至4周后进行第二次补打治疗以处理可能出现的不对称情况。随后进行了4次访视,最后一次访视在首次注射后9个月进行以便从临床和仪器方面评估治疗效果。
首次注射后访视时记录到面颊容积有临床和统计学上的显著改善,且该效果一直维持到研究期结束。还观察到皱纹严重程度有临床上可测量的改善。通过3D图像记录及随后的定量分析,能够确定在增加面部容积方面的效果,在首次访视时就已明显,在第二次和第三次访视时进一步增加,并在第四次也是最后一次访视时得以维持。根据志愿者的自我评估问卷,志愿者对注射的耐受性非常好。
研究结果证实了研究产品对与年龄相关的面部中部容积缺陷的美学表现。研究产品非常强的高容积活性不仅得到了研究者的恰当判定,也得到了志愿者自我评估的证实。这些效果在没有明显不良影响的情况下获得。